The magnitude of OS benefit with upfront HDT is cytogenetics-dependent. Patients with high-risk cytogenetics should preferably receive upfront rather...
This makes an interdisciplinary approach mandatory for the management of these patients, to provide the best care possible based on tumor size, site...
This is likely attributable to underlying disease biology and prevention of end-organ damage by early treatment initiation, as benefit was independent...